Inari Medical (NARI) Scheduled to Post Earnings on Tuesday

Inari Medical (NASDAQ:NARI) is scheduled to post its quarterly earnings results after the market closes on Tuesday, April 30th. Analysts expect Inari Medical to post earnings of ($0.16) per share for the quarter. Inari Medical has set its FY 2024 guidance at EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Inari Medical (NASDAQ:NARI) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.09). The firm had revenue of $132.10 million for the quarter, compared to analyst estimates of $131.82 million. Inari Medical had a negative net margin of 0.33% and a positive return on equity of 1.23%. The company’s revenue was up 22.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.11) EPS. On average, analysts expect Inari Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Inari Medical Price Performance

Shares of NARI stock opened at $37.93 on Tuesday. The company’s 50-day moving average price is $46.48 and its 200-day moving average price is $54.98. Inari Medical has a twelve month low of $36.73 and a twelve month high of $71.85.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $75.00 price target on shares of Inari Medical in a research report on Friday, April 12th. Piper Sandler cut shares of Inari Medical from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $85.00 to $55.00 in a research report on Thursday, February 29th. Needham & Company LLC reissued a “buy” rating and set a $72.00 price target on shares of Inari Medical in a research report on Wednesday, March 6th. Finally, Truist Financial lowered their price target on shares of Inari Medical from $61.00 to $52.00 and set a “hold” rating on the stock in a research report on Friday, March 22nd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $73.71.

Insider Buying and Selling at Inari Medical

In other Inari Medical news, Director William Hoffman sold 40,000 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $41.13, for a total value of $1,645,200.00. Following the transaction, the director now owns 1,003,296 shares of the company’s stock, valued at $41,265,564.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CFO Mitch C. Hill sold 6,000 shares of the stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $40.96, for a total transaction of $245,760.00. Following the sale, the chief financial officer now owns 181,294 shares of the company’s stock, valued at $7,425,802.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William Hoffman sold 40,000 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $41.13, for a total transaction of $1,645,200.00. Following the sale, the director now directly owns 1,003,296 shares in the company, valued at approximately $41,265,564.48. The disclosure for this sale can be found here. Insiders have sold 47,451 shares of company stock valued at $1,949,000 over the last 90 days. 10.60% of the stock is owned by insiders.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.